Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights

– Product development focused on the production of powder formulations of oat beta glucan and avenanthramides for cosmeceuticals market – Technology development focused on the PGX pilot...

Related Keywords

Austria ,Canada ,China ,Montreal ,Quebec ,Vienna ,Wien ,Canadian ,Austrian ,Gilles Gagnon ,Beta Glucan ,Prozesstechnologie Gmb ,Jenene Thomas ,Corealis Inc ,Ceapro Inc ,Angiogenesis Foundation ,Nasdaq ,Energy Booster ,Mcmaster University ,Montreal Heart Institute ,Pipeline Development ,Manufacturing Services ,Expanded Technology ,Technology Avenanthramides ,Clinical Development ,Corporate Communications Advisor ,Clinical Trial ,Healing Tissue Regeneration ,Third Quarter ,Nine Month Period Ended September ,Interim Consolidated Balance Sheets ,Interim Consolidated Statements ,Cash Flows ,Months Ended September ,Corporate Communications ,Markets ,